{"disease":{"id":"neck","name":"neck"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"immuno-oncology-io","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"borofalan-10b","indication_name":"Neoplasm of head and neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steboronine","generic_name":"borofalan (10B)","company_name":"Stella Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"diclofenac","indication_name":"Neckshoulderarm syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voltaren","generic_name":"DICLOFENAC","company_name":"Hisamitsu Pharmaceutical Co., Inc","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Nonsteroidal Anti-inflammatory Drug","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bleomycin","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pembrolizuma","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"taxotere","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxotere","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"docetaxol","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Docetaxol","company_name":"Fudan University","drug_phase":"phase_2","molecular_target":"Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxyurea","indication_name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"fytic-acid","indication_name":"Lymphoscintigraphy in cervical cancer, uterine neoplasms, vulvar cancer, and head and neck canccer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phyliance","generic_name":"fytic acid","company_name":"PDRadiopharma Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"arthrotec","indication_name":"Neckshoulderarm syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arthrotec","generic_name":"Diclofenac Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acid-sensing ion channel 3","drug_class":"diclofenac","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"temoporfin","indication_name":"Neoplasm of head and neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscan","generic_name":"TEMOPORFIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"temoporfin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"docetaxel","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxotere","generic_name":"Docetaxel","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Growth hormone-releasing hormone receptor","drug_class":"Microtubule Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division."},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"methotrexate","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamide","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"erbitux","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Malignant tumor of head and/or neck","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Head and neck squamous cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cetuximab","indication_name":"Head and neck cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."}],"pipeline":[{"drug_id":"pf-06940434","indication_name":"Squamous Cell Carcinoma of the Head and Neck","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06940434","generic_name":"pf-06940434","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","quality_score":null,"revenue":null,"mechanism":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2"}],"offLabel":[],"totalMarketed":28,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT06494670","title":"Trends in Prevalence of 11 Site-specific Musculoskeletal Pain Among U.S. Adults, 1999-2018","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":565219,"lead_sponsor_name":"Fan luying","has_results":false},{"nct_id":"NCT05745129","title":"Applying Artificial Intelligence in Developing Personalized and Sustainable Healthcare for Spinal Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":165000,"lead_sponsor_name":"Oslo Metropolitan University","has_results":false},{"nct_id":"NCT03157674","title":"Real-World Evidence and Treatment Patterns: Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":43994,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07290361","title":"Stratified Targeted Engagement From Primary Care to Physical Therapy (STEPPT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":17587,"lead_sponsor_name":"San Diego State University","has_results":false},{"nct_id":"NCT07204405","title":"Haemorrhage From Severe Neck and Facial Injuries - Characteristics, Management and Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":15000,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT05483374","title":"The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":13600,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT05776771","title":"The Spine Phenome Project","phase":"","overall_status":"RECRUITING","enrollment_count":10500,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT05117775","title":"Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Savana Research","has_results":false},{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05164081","title":"Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT06248944","title":"AIOCC Italian Registry on Head and Neck Carcinomas","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Italian Head&Neck Society","has_results":false},{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04081896","title":"Evaluation of the Effects of a Rehabilitation Program in Individuals with Spine Pain","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"SpineZone Medical Fitness, Inc","has_results":false},{"nct_id":"NCT00991094","title":"Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06335342","title":"Radiotherapy Treatments for Neoplasms in the Head and Neck Region","phase":"","overall_status":"UNKNOWN","enrollment_count":4050,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT02786966","title":"A Pragmatic Evaluation of the Canadian C-Spine Rule by Paramedics","phase":"NA","overall_status":"COMPLETED","enrollment_count":3646,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":true},{"nct_id":"NCT02017288","title":"Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":3576,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04719936","title":"Superior and Inferior Capsulotomy in Bipolar Hemiarthroplasty Using Posterior Approach","phase":"NA","overall_status":"COMPLETED","enrollment_count":3502,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05936502","title":"Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3500,"lead_sponsor_name":"Head and Neck Cancer International Group","has_results":false},{"nct_id":"NCT04825873","title":"A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China","phase":"","overall_status":"COMPLETED","enrollment_count":3102,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03083886","title":"Spine Pain INtervention to Enhance Care Quality And Reduce Expenditure","phase":"NA","overall_status":"COMPLETED","enrollment_count":3087,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT06773039","title":"Assessment of Different Therapeutic Strategies in Patients With Head and Neck Neoplasms Treated With Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07532538","title":"A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04825834","title":"DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)","phase":"","overall_status":"COMPLETED","enrollment_count":2992,"lead_sponsor_name":"Delfi Diagnostics Inc.","has_results":false},{"nct_id":"NCT03393143","title":"A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain","phase":"","overall_status":"COMPLETED","enrollment_count":2748,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT03326271","title":"Postoperative Periprosthetic Fractures in Hip Fracture Patients: Exeter vs Anatomic SP2 Lubinus Stem","phase":"","overall_status":"COMPLETED","enrollment_count":2527,"lead_sponsor_name":"Sundsvall Hospital","has_results":false},{"nct_id":"NCT04905030","title":"Education, Immigration and HPV Vaccination: an Informational Randomized Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03702309","title":"Liquid Biopsy Evaluation and Repository Development at Princess Margaret","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03162952","title":"RAND Center of Excellence for the Study of Appropriateness of Care in CAM","phase":"","overall_status":"COMPLETED","enrollment_count":2025,"lead_sponsor_name":"RAND","has_results":false},{"nct_id":"NCT04326088","title":"Postoperative Complication After Free Flap Reconstruction for Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04655469","title":"Personal Health Train for Radiation Oncology in India and The Netherlands","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT06402409","title":"Exploring Multimorbidity in Patients With Spinal Pain","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Jacob Christiansen Gandløse","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04949503","title":"A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN","phase":"","overall_status":"COMPLETED","enrollment_count":1931,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06438640","title":"Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1881,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04475640","title":"Cancer Genetic Testing in Ethnic Populations","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00530049","title":"Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure","phase":"","overall_status":"COMPLETED","enrollment_count":1745,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05050162","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":1714,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT00963911","title":"Validation of a Screening Tool in Geriatric Oncology","phase":"NA","overall_status":"COMPLETED","enrollment_count":1674,"lead_sponsor_name":"Institut Bergonié","has_results":true},{"nct_id":"NCT03909815","title":"Dual Mobility Cups in Hip Fracture Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT04002713","title":"Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1590,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04478851","title":"EXCEL: Exercise for Cancer to Enhance Living Well","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT05187923","title":"Computer Aided Tool for Diagnosis of Neck Masses in Children","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03301493","title":"Genomic Testing and Resulting Medical Decisions","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT03523793","title":"Clinical Practice Guidelines for Neck and Low Back Pain in Outpatient Physical Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":1441,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT03966716","title":"Hips Screws or (Total) Hip Replacement for Undisplaced Femoral Neck Fractures in Elderly Patients (HipSTHeR)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1440,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05697198","title":"PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":1429,"lead_sponsor_name":"Labcorp Corporation of America Holdings, Inc","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}